Jonathan Kay (J Kay)

ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 36

Top Venues

Annals of the rheumatic diseases

RMD open

Arthritis & rheumatology (Hoboken, N.J.)

Arthritis care & research

University of Massachusetts Medical School

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Massachusetts Medical School Jul 01 2009

United States

Timothy S. and Elaine L. Peterson Chair in Rheumatology & Professor of Medicine :: Medicine

Brigham and Women's Hospital

United States

Research Fellow in Rheumatology & Immunology :: Rheumatology & Immunology

Brigham and Women's Hospital

United States

Clinical Fellow in Rheumatology :: Rheumatology & Immunology

Hospital of the University of Pennsylvania

United States

Resident in Medicine :: Medicine

Hospital of the University of Pennsylvania

United States

Intern in Medicine :: Medicine

Publications

Divya Shridharmurthy, Kate L Lapane, Jonggyu Baek, Anthony P Nunes, Michael H Weisman, Jonathan Kay, Shao-Hsien Liu
Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis. Arthritis care & research (2024)
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John Dudley Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie J Crofford, Ronald F Van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Thomas Wj Huizinga, Ellen M Gravallese
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Annals of the rheumatic diseases 83 (4) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John Dudley Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie J Crofford, Ronald F Van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Thomas Wj Huizinga, Ellen M Gravallese
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Annals of the rheumatic diseases 83 (4) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Jonathan Kay, Nikolay P Nikolov, Michael H Weisman, null null
American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting, May 17-18, 2022. Arthritis & rheumatology (Hoboken, N.J.) 76 (9) (2024)
Divya Shridharmurthy, Kate L Lapane, Jonggyu Baek, Anthony P Nunes, Michael H Weisman, Jonathan Kay, Shao-Hsien Liu
Sex differences in time to initiate NSAIDs or bDMARDs among patients with axial spondyloarthritis. Arthritis care & research (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Jonathan Kay, Nikolay P Nikolov, Michael H Weisman, null null
American College of Rheumatology (ACR) and Food and Drug Administration (FDA) Summit: Summary of the Meeting May 17-18, 2022. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Jonathan Kay, Nikolay P Nikolov, Michael H Weisman, null null
American College of Rheumatology and Food and Drug Administration Summit: Summary of the Meeting May 17-18, 2022. Arthritis & rheumatology (Hoboken, N.J.) (2024)
Divya Shridharmurthy, Kate L Lapane, Jonggyu Baek, Anthony P Nunes, Michael H Weisman, Jonathan Kay, Shao-Hsien Liu
Sex Differences in Time to Initiate Nonsteroidal Anti-Inflammatory Drugs or Biologic Disease-Modifying Antirheumatic Drugs Among Patients With Axial Spondyloarthritis. Arthritis care & research 76 (8) (2024)
Victoria Navarro-Compán, Josef S Smolen, Atul Deodhar, Phillip J Mease, Martin Rudwaleit, Christine de la Loge, Carmen Fleurinck, Vanessa Taieb, Michael F Mørup, Ute Massow, Jonathan Kay, Marina Magrey
Association of clinical response criteria and disease activity levels with axial spondyloarthritis core domains: results from two phase 3 randomised studies, BE MOBILE 1 and 2. RMD open 10 (2) (2024)
Kevin L Winthrop, Philip Mease, Andreas Kerschbaumer, Reinhard E Voll, Ferdinand C Breedveld, Josef S Smolen, Jacques-Eric Gottenberg, Xenofon Baraliakos, Hans P Kiener, Daniel Aletaha, John Dudley Isaacs, Maya H Buch, Mary K Crow, Jonathan Kay, Leslie J Crofford, Ronald F Van Vollenhoven, Caroline Ospelt, Stefan Siebert, Margreet Kloppenburg, Iain B McInnes, Thomas Wj Huizinga, Ellen M Gravallese
Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023. Annals of the rheumatic diseases (2023)
Jonathan Kay, Amy E Bock, Muhammad Rehman, Wuyan Zhang, Min Zhang, Noriko Iikuni, Daniel F Alvarez
Use of multibiomarker disease activity scores in biosimilarity studies for the treatment of patients with rheumatoid arthritis. RMD open 8 (2) (2022)
Eric P Rahrmann, David Shorthouse, Amir Jassim, Linda P Hu, Mariaestela Ortiz, Betania Mahler-Araujo, Peter Vogel, Marta Paez-Ribes, Atefeh Fatemi, Gregory James Hannon, Radhika Iyer, Jay A Blundon, Filipe C Lourenço, Jonathan Kay, Rosalynn M Nazarian, Michael W J Hall, Stanislav S Zakharenko, Douglas J Winton, Liqin Zhu, Richard J Gilbertson
The NALCN channel regulates metastasis and nonmalignant cell dissemination. Nature genetics 54 (12) (2022)
Divya Shridharmurthy, Kate L Lapane, Sara Khan, Esther Yi, Jonggyu Baek, Jonathan Kay, Shao-Hsien Liu
Development and test-retest reliability of a screening tool for axial spondyloarthritis. PloS one 17 (7) (2022)
Jonathan Kay, Masayoshi Harigai, Josh Rancourt, Christina Dickson, Thomas Melby, Maher Issa, Inmaculada de la Torre, Yoshitaka Isaka, Anabela Cardoso, Chadi Saifan, Edward C Keystone, Ronald F Van Vollenhoven, Jon T Giles, Thomas Wj Huizinga, Joel M Kremer
Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib. RMD open 6 (3) (2021)
René Westhovens, William F C Rigby, Désirée Mfm van der Heijde, Daniel W T Ching, William Stohl, Jonathan Kay, Arvind Chopra, Beatrix Bartok, Franziska Matzkies, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S Sundy, Angelika Jahreis, Neelufar Mozaffarian, Osvaldo Daniel Messina, Robert B M Landewe, Tatsuya Atsumi, Gerd R Burmester
Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Annals of the rheumatic diseases (2021)
Catherine E Dube, Kate L Lapane, Katarina A Ferrucci, Ariel L Beccia, Sara K Khan, Esther Yi, Jonathan Kay, Kristine A Kuhn, Alexis Ogdie, Shao-Hsien Liu
Personal Experiences with Diagnostic Delay Among Axial Spondyloarthritis Patients: A Qualitative Study. Rheumatology and therapy 8 (2) (2021)
Shao-Hsien Liu, Divya Shridharmurthy, Kate L Lapane, Catherine E Dubé, Ellen M Gravallese, Jonathan Kay
Physical Activity and Attitudes Toward Exercise in People With Axial and Peripheral Spondyloarthritis. The Journal of rheumatology 48 (4) (2020)
Woojin Joo, Christopher V Almario, Mariko Ishimori, Yujin Park, Alma Jusufagic, Benjamin Noah, Lianne S Gensler, R Swamy Venuturupalli, Jonathan Kay, Michael H Weisman, Brennan M R Spiegel
Examining Treatment Decision-Making Among Patients With Axial Spondyloarthritis: Insights From a Conjoint Analysis Survey. ACR open rheumatology 2 (7) (2020)
Joshua F Baker, Charles E Leonard, Vincent Lo Re, Michael H Weisman, Michael D George, Jonathan Kay
Biosimilar Uptake in Academic and Veterans Health Administration Settings: Influence of Institutional Incentives. Arthritis & rheumatology (Hoboken, N.J.) 72 (7) (2020)
Jonathan Kay
Overcoming barriers to biosimilars in inflammatory arthritis. Nature reviews. Rheumatology 16 (2) (2020)
Eldin Dzubur, Carine Khalil, Christopher V Almario, Benjamin Noah, Deeba Minhas, Mariko Ishimori, Corey W Arnold, Yujin Park, Jonathan Kay, Michael H Weisman, Brennan Mason Ross Spiegel
Patient Concerns and Perceptions Regarding Biologic Therapies in Ankylosing Spondylitis: Insights From a Large-Scale Survey of Social Media Platforms. Arthritis care & research 71 (2) (2019)
Jonathan Kay
A 'wind of change' to biosimilars: The NOR-SWITCH trial and its extension. Journal of internal medicine 285 (6) (2019)
Kevin L Winthrop, Michael E Weinblatt, Mary K Crow, Gerd R Burmester, Phillip J Mease, Alexander K So, Vivian Bykerk, Ronald F Van Vollenhoven, Maxime Dougados, Jonathan Kay, Xavier Mariette, Joachim Sieper, Fritz Melchers, Bruce N Cronstein, Ethan Shevach, Ferdinand C Breedfeld, Joachim Kalden, Josef S Smolen, Daniel E Furst
Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. Annals of the rheumatic diseases 78 (7) (2019)
Jonathan Kay, Thomas Dörner, Paul Emery, Tore K Kvien, Ferdinand C Breedveld
Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar. Annals of the rheumatic diseases 79 (4) (2019)
Atul Deodhar, Lianne S Gensler, Jonathan Kay, Walter P Maksymowych, Nigil Haroon, Robert Landewé, Martin Rudwaleit, Stephen Hall, Lars Bauer, Bengt Hoepken, Natasha de Peyrecave, Brian Kilgallen, Désirée van der Heijde
A Fifty-Two-Week, Randomized, Placebo-Controlled Trial of Certolizumab Pegol in Nonradiographic Axial Spondyloarthritis. Arthritis & rheumatology (Hoboken, N.J.) 71 (7) (2019)
S Louis Bridges, Douglas W White, Angus B Worthing, Ellen M Gravallese, James R O'Dell, Kamala Nola, Jonathan Kay, Stanley B Cohen, null null
The Science Behind Biosimilars: Entering a New Era of Biologic Therapy. Arthritis & rheumatology (Hoboken, N.J.) 70 (3) (2018)
Gerd R Burmester, William F Rigby, Ronald F van Vollenhoven, Jonathan Kay, Andrea Rubbert-Roth, Ricardo Blanco, Alysha Kadva, Sophie Dimonaco
Tocilizumab combination therapy or monotherapy or methotrexate monotherapy in methotrexate-naive patients with early rheumatoid arthritis: 2-year clinical and radiographic results from the randomised, placebo-controlled FUNCTION trial. Annals of the rheumatic diseases 76 (7) (2017)
Jonathan Kay, Monika M Schoels, Thomas Dörner, Paul Emery, Tore K Kvien, Josef S Smolen, Ferdinand C Breedveld, null null
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Annals of the rheumatic diseases 77 (2) (2017)
U Kiltz, Josef S Smolen, T Bardin, A Cohen Solal, N Dalbeth, M Doherty, B Engel, C Flader, Jonathan Kay, M Matsuoka, F Perez-Ruiz, G da Rocha Castelar-Pinheiro, K Saag, A So, J Vazquez Mellado, M Weisman, T H Westhoff, H Yamanaka, J Braun
Treat-to-target (T2T) recommendations for gout. Annals of the rheumatic diseases 76 (4) (2016)
Atul A Deodhar, Vibeke Strand, Jonathan Kay, Juergen Braun
The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Annals of the rheumatic diseases 75 (5) (2016)
Jonathan Kay, John D Isaacs
Clinical trials of biosimilars should become more similar. Annals of the rheumatic diseases 76 (1) (2016)
Thomas Dörner, Vibeke Strand, Paul Cornes, João Gonçalves, László Gulácsi, Jonathan Kay, Tore K Kvien, Josef S Smolen, Yoshiya Tanaka, Gerd R Burmester
The changing landscape of biosimilars in rheumatology. Annals of the rheumatic diseases 75 (6) (2016)
Gerd R Burmester, William F Rigby, Ronald F van Vollenhoven, Jonathan Kay, Andrea Rubbert-Roth, Ariella Kelman, Sophie Dimonaco, Nina Mitchell
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Annals of the rheumatic diseases 75 (6) (2015)
Christian Schmidt-Lauber, Lukas Bossaller, Hani H Abujudeh, Gregory I Vladimer, Anette Christ, Katherine A Fitzgerald, Eicke Latz, Ellen M Gravallese, Ann Marshak-Rothstein, Jonathan Kay
Gadolinium-based compounds induce NLRP3-dependent IL-1β production and peritoneal inflammation. Annals of the rheumatic diseases 74 (11) (2014)

Jonathan Kay.css-eqlu8i{font-size:small;padding-left:4px;} (J Kay)

Publication Activity (10 Years)

Top Topics

Top Venues

Jonathan Kay (J Kay)